3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
Titel:
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
Auteur:
Pérez-García, José Manuel Cortés, Javier Ruiz-Borrego, Manuel Colleoni, Marco Stradella, Agostina Bermejo, Begoña Dalenc, Florence Escrivá-de-Romaní, Santiago Calvo Martínez, Lourdes Ribelles, Nuria Marmé, Frederik Cortés, Alfonso Albacar, Cinta Gebhart, Geraldine Prat, Aleix Kerrou, Khaldoun Schmid, Peter Braga, Sofia Di Cosimo, Serena Gion, Maria Antonarelli, Gabriele Popa, Crina Szostak, Emilia Alcalá-López, Daniel Gener, Petra Rodríguez-Morató, Jose Mina, Leonardo Sampayo-Cordero, Miguel Llombart-Cussac, Antonio